

31 July 2026

## June 2026 Quarter Activities Update

### Highlights

- Secured A\$1.4 million Phase II contract from Uviquity under Joint Development Agreement
- Entered A\$1.3 million development agreement with a Fortune 500 global data storage leader
- Achieved new world-record 1.9W of peak output power from a single-mode blue GaN laser
- Received initial order from strategic data centre customer
- Raised A\$14.6 million from institutional Placement, Options exercise and shortfall agreement

**BluGlass Limited (ASX: BLG)**, a global semiconductor developer pioneering visible lasers, provides the following update and Appendix 4C Quarterly Report for the three months ended 30 June 2026 (Q4 FY26).

**CEO and Managing Director Jim Haden said:** *"BluGlass has had a strong finish to the 2026 fiscal year with multiple paid development contracts with government and Tier 1 customers progressing to schedule. At the same time, we're continuing to advance opportunities within our US\$100 million project pipeline while also engaging with prospective new customers on semi-custom laser solutions to solve specific application challenges. Our Phase II agreement with Uviquity reinforces our growing industry reputation, expands our product portfolio, and supports project conversion. Alongside our core target verticals, we're seeing increased interest from emerging AI and data centre applications where advanced photonic technologies are being deployed to overcome bandwidth, latency and power-consumption constraints."*

*"While BluGlass is a relatively new laser company compared to our more established and much larger peers, our single-mode gallium nitride (GaN) lasers continue to set new industry performance standards. Our recent world-record for peak power output demonstrates the cutting-edge precision and power our lasers offer, benefitting from our team's proprietary epitaxy to fabrication know-how. Paid development projects are also supporting novel capabilities."*

*"Our strong commercial and technical progress over the quarter highlight our GaN laser leadership, and demonstrate that our technology, product roadmap and commercialisation strategy are gaining meaningful traction with industry heavyweights. The quality of our customer base is a significant endorsement of our technical capability, and we remain focused on embedding our visible laser technology into next-generation customer applications during development. This approach creates immediate revenues as well as the potential for future manufacturing and supply agreements."*

**Executive Chair Omer Granit said:** *"BluGlass delivered significant strategic progress over the quarter, strengthening its commercial position, industry reputation and capital markets profile. In line with our refreshed commercialisation strategy, we are broadening our presence in the United States with increased engagement across customers, government stakeholders, industry leaders and investors."*

*“Our focus remains on building BluGlass into the leading U.S. on-and-near-shore visible laser company. We’re continuing to convert more opportunities from our growing commercial pipeline, while also actively positioning BluGlass to access deeper pools of capital to support our long-term growth ambitions.*

*“Shareholder support during the quarter has been exceptional, enabling us to add A\$14.6 million to our balance sheet through the successful completion of an institutional capital raise, Board and management investment, exercise of options and shortfall agreement. As BluGlass continues to achieve new technical and commercial milestones, the market is increasingly recognising the significant opportunity ahead of us with macro tailwinds underpinning material sector growth.”*

#### **A\$1.4 million contract from Uviquity**

In July, BluGlass received a A\$1.4 million (US\$1 million) contract from U.S. photonics company Uviquity for Phase II of its Joint Development Agreement (JDA). Phase II builds on the successful first stage, broadening the collaboration from research and development of Uviquity’s heterogeneously integrated photonic integrated circuit (PIC) platform to include additional engineering, novel packaging, laser integration and purchases of BluGlass’ visible GaN lasers.

Uviquity develops chip-based deep-ultraviolet light sources on an aluminum nitride (AlN) PIC platform for human-safe far-UVC disinfection at scale and deep-UV sensing and analytical instrumentation. The company has recently demonstrated the world’s first chip-scale deep-UV laser at 229nm for analytical and inspection applications across the semiconductor, pharmaceutical, environmental and defence markets.

#### **A\$1.3 million agreement with a Fortune 500 company**

During the quarter, BluGlass entered a A\$1.3 million collaboration with a global leader in mass-capacity data storage. Under the agreement, BluGlass is leveraging its visible GaN laser and custom semiconductor development capabilities to support the customer’s next-generation photonics development activities. The \$1.3 million agreement will be paid in four instalments tied to activity-based milestones, expected to be completed over the next 12-18 months.

#### **Initial order from strategic AI infrastructure customer**

BluGlass has secured an initial order of its GaN surface emitting lasers from a strategic stealth-mode customer developing next-generation optical interconnect technologies intended to support future AI computing and data centre infrastructure. Unlike typical edge emitting lasers that amplify light horizontally, surface emitting lasers amplify and emit light vertically and are predominantly used in low-power consumer and data communication applications.

While revenue from the initial purchase order is not material, the engagement has the potential to expand into a broader development program and ultimately a long-term commercial relationship.

#### **New world-record single-mode performance**

BluGlass significantly enhanced the technical performance of its single-mode GaN lasers during the quarter, achieving a world-record 1.9W of single-spatial mode power – a 52% improvement over the Company’s previous record of 1.25W. This achievement reinforces the suitability of BluGlass’ visible lasers for high-power, high-precision applications across defence, aerospace, quantum and industrial domains.

The record was achieved using the Company’s blue 450nm single-mode GaN laser with its proprietary gain-chip technology, incorporating a single-mode master oscillator with a tapered power amplifier (MOPA) to materially increase power while maintaining high precision. The technical milestone further differentiates BluGlass’ laser platform for applications requiring both high optical power and high beam quality.

#### **Raised \$14.6 million**

BluGlass strengthened its balance sheet during the quarter, raising a combined \$14.6 million from an institutional Placement, exercise of Options, and a shortfall agreement with Amery Partners Pty Ltd. An upsized \$8 million

Placement to institutional investors was supported by a \$2.3 million cornerstone investment by Board and Management. The Placement was conducted at \$0.24 per share and included one free attaching option exercisable at \$0.38 and expiring on 31 May 2028.

Exercised \$0.26 Options contributed \$5.06 million and the Company received \$1.5 million under a shortfall agreement with Amery Partners Pty Ltd. All exercised options and issued shortfall shares included one unquoted free-attaching option on the same terms as the Placement. Attaching options associated with shortfall shares are subject to shareholder approval at the Company's 2026 Annual General Meeting.

### Strategic Uviquity investment

BluGlass made a US\$1.5 million strategic investment in U.S.-based integrated photonics company Uviquity via the issue of a convertible note. Uviquity is an existing customer and development partner whose photonics roadmap complements BluGlass' advanced laser capabilities. The investment strengthens BluGlass's position in emerging photonics, quantum, sensing and advanced packaging markets and provides potential future equity participation in a strategically aligned company operating in a complementary segment of the photonics market. The key terms of the convertible note include an interest rate of 6%, 12-month maturity date and standard conversion mechanisms including the right to convert (or redeem) at maturity and automatic conversion at a discount on a qualified financing.

### Strategic U.S. Govt and defence engagements

During the quarter, BluGlass showcased its visible GaN laser technology at SPIE Defense + Security, the leading U.S. conference for defence photonics and sensing technologies. CEO Jim Haden and Executive VP Brad Siskavich met with prospective customers, government stakeholders and industry partners to demonstrate BluGlass' advanced laser capabilities and support the continued expansion of the Company's development pipeline.

BluGlass also participated in several invitation-only U.S. Government and defence industry engagements, including a U.S. Navy industry gathering in Seattle and a roundtable with the Hon. Michael Dodd, U.S. Assistant Secretary for Critical Technologies. Focused on advanced underwater technologies and future capability requirements, the Navy event generated multiple requests for additional information and follow-on meetings to further explore GaN's enabling capabilities in Subsea and Seabed Warfare (SSW).

The invitation-only directed-energy roundtable in Washington, D.C. centered on accelerating the development and deployment of directed-energy systems - a key focus area for the Department's critical technology portfolio. Mr Haden discussed the potential of BluGlass' advanced visible lasers for future directed-energy systems and related defence applications with Assistant Secretary Dodd and his advisor, Colonel Jake Hess.

### Semiconductor Australia

BluGlass has divested its majority stake in the nation's premier semiconductor conference, Semiconductor Australia, to focus on its core GaN laser business. The Company remains a minority shareholder with branding rights and profit share. *Semiconductor Australia 2026* is being held in Sydney on 22 October 2026 and will feature keynote presentations from Chair of the National Reconstruction Fund, Martijn Wilder AM, and Dr Larry Marshall, Lead Independent Director of Fortescue Innovation.

### Jim Haden appointed Managing Director

In July, BluGlass appointed CEO and Executive Director Jim Haden to the role of Managing Director. The new title reflects Mr Haden's management responsibilities and aligns with standard market practice.

### Financials

Quarterly customer receipts of \$200k included the NCSU development contract and product laser orders. R&D development expenditure during the quarter was \$3.01 million, inclusive of salaries, materials and fabrication costs for laser product development. R&D investment remains aligned with the Company's commercialisation roadmap and customer-driven development projects.

Payments to related parties during the quarter were \$178k encompassing Executive Chair and Non-Executive Director fees.

Cash and cash equivalents at the end of the quarter were \$11.48 million. Following the successful capital raising completed during the quarter, BluGlass is well funded to advance its commercialisation strategy, progress customer-funded development programs and pursue opportunities within its growing pipeline while continuing to actively manage costs.

### Investor briefing details

Executive Chair Omer Granit and CEO Jim Haden will participate in an investor webinar covering the Company's quarterly update on 4 August 2026 at 3:30pm AEST. Attendees will have an opportunity to ask questions.

To attend, please pre-register at [https://us02web.zoom.us/webinar/register/WN\\_w4fj0x7bS1aY11d0GV7I\\_A](https://us02web.zoom.us/webinar/register/WN_w4fj0x7bS1aY11d0GV7I_A)

**This announcement has been approved for release by the BluGlass Board.**

---

### For more information, please contact:

Samuel Samhan, BluGlass CFO | +61 2 9334 2300 | [ssamhan@bluglass.com.au](mailto:ssamhan@bluglass.com.au)

James Lennon, Automic Markets | +61 414 035 704 | [james.lennon@automicgroup.com.au](mailto:james.lennon@automicgroup.com.au)

### About BluGlass

**BluGlass Limited (ASX:BLG)** is a leading supplier of GaN laser diode products to the global photonics industry, focused on the industrial, defense, bio-medical, and scientific markets.

Listed on the ASX, BluGlass is one of just a handful of end-to-end GaN laser manufacturers globally. Its operations in Australia and the US offer cutting-edge, custom laser diode development and manufacturing, from small-batch custom lasers to medium and high-volume off-the-shelf products.

The Company combines its proprietary low temperature, low hydrogen, remote plasma chemical vapour deposition (RPCVD) manufacturing process with advanced device design and fabrication to deliver differentiated laser solutions. With end-to-end capabilities spanning epitaxy, device design, fabrication, and testing, BluGlass is well-positioned to support critical next-generation photonics applications and sovereign supply chains.

## Appendix 4C

### Quarterly cash flow report for entities subject to Listing Rule 4.7B

**Name of entity**

BluGlass Limited

**ABN**

20 116 625 793

**Quarter ended ("current quarter")**

30 June 2026

| <b>Consolidated statement of cash flows</b>               | <b>Current quarter<br/>\$A'000</b> | <b>Year to date<br/>(12 months)<br/>\$A'000</b> |
|-----------------------------------------------------------|------------------------------------|-------------------------------------------------|
| <b>1. Cash flows from operating activities</b>            |                                    |                                                 |
| 1.1 Receipts from customers                               | 201                                | 4,226                                           |
| 1.2 Payments for                                          |                                    |                                                 |
| (a) research and development                              | (1,617)                            | (6,343)                                         |
| (b) product manufacturing and operating costs             |                                    |                                                 |
| (c) advertising and marketing                             | (41)                               | (362)                                           |
| (d) leased assets                                         | (332)                              | (1,373)                                         |
| (e) staff costs                                           | (2,109)                            | (8,649)                                         |
| (f) administration and corporate costs                    | (560)                              | (1,695)                                         |
| 1.3 Dividends received (see note 3)                       |                                    |                                                 |
| 1.4 Interest received                                     | 2                                  | 18                                              |
| 1.5 Interest and other costs of finance paid              |                                    |                                                 |
| 1.6 Income taxes paid                                     |                                    |                                                 |
| 1.7 Government grants and tax incentives                  | -                                  | 6,069                                           |
| 1.8 Other (provide details if material)                   |                                    |                                                 |
| <b>1.9 Net cash from / (used in) operating activities</b> | <b>(4,456)</b>                     | <b>(8,109)</b>                                  |
| <b>2. Cash flows from investing activities</b>            |                                    |                                                 |
| 2.1 Payments to acquire or for:                           |                                    |                                                 |
| (a) entities                                              |                                    |                                                 |
| (b) businesses                                            |                                    |                                                 |
| (c) property, plant and equipment                         | (318)                              | (1,215)                                         |
| (d) investments                                           |                                    |                                                 |
| (e) intellectual property                                 |                                    |                                                 |

| Consolidated statement of cash flows |                                                       | Current quarter<br>\$A'000 | Year to date<br>(12 months)<br>\$A'000 |
|--------------------------------------|-------------------------------------------------------|----------------------------|----------------------------------------|
|                                      | (f) other non-current assets (security deposits)      | 220                        | 220                                    |
| 2.2                                  | Proceeds from disposal of:                            |                            |                                        |
|                                      | (a) entities                                          |                            |                                        |
|                                      | (b) businesses                                        |                            |                                        |
|                                      | (c) property, plant and equipment                     | -                          | 66                                     |
|                                      | (d) investments                                       |                            |                                        |
|                                      | (e) intellectual property                             |                            |                                        |
|                                      | (f) other non-current assets                          |                            |                                        |
| 2.3                                  | Cash flows from loans to other entities               |                            |                                        |
| 2.4                                  | Dividends received (see note 3)                       |                            |                                        |
| 2.5                                  | Other (provide details if material)                   |                            |                                        |
| 2.6                                  | <b>Net cash from / (used in) investing activities</b> | <b>(98)</b>                | <b>(929)</b>                           |

|           |                                                                                         |               |               |
|-----------|-----------------------------------------------------------------------------------------|---------------|---------------|
| <b>3.</b> | <b>Cash flows from financing activities</b>                                             |               |               |
| 3.1       | Proceeds from issues of equity securities (excluding convertible debt securities)       | 9,548         | 9,548         |
| 3.2       | Proceeds from issue of convertible debt securities                                      |               |               |
| 3.3       | Proceeds from exercise of options                                                       | 4,620         | 5,065         |
| 3.4       | Transaction costs related to issues of equity securities or convertible debt securities | (763)         | (1,214)       |
| 3.5       | Proceeds from borrowings                                                                | -             | 4,540         |
| 3.6       | Repayment of borrowings                                                                 | -             | (3,048)       |
| 3.7       | Transaction costs related to loans and borrowings                                       | -             | (259)         |
| 3.8       | Dividends paid                                                                          |               |               |
| 3.9       | Other (provide details if material)                                                     |               |               |
| 3.10      | <b>Net cash from / (used in) financing activities</b>                                   | <b>13,405</b> | <b>14,632</b> |

|           |                                                                              |         |         |
|-----------|------------------------------------------------------------------------------|---------|---------|
| <b>4.</b> | <b>Net increase / (decrease) in cash and cash equivalents for the period</b> |         |         |
| 4.1       | Cash and cash equivalents at beginning of period                             | 2,724   | 5,953   |
| 4.2       | Net cash from / (used in) operating activities (item 1.9 above)              | (4,456) | (8,109) |

| Consolidated statement of cash flows |                                                                     | Current quarter<br>\$A'000 | Year to date<br>(12 months)<br>\$A'000 |
|--------------------------------------|---------------------------------------------------------------------|----------------------------|----------------------------------------|
| 4.3                                  | Net cash from / (used in) investing activities<br>(item 2.6 above)  | (98)                       | (929)                                  |
| 4.4                                  | Net cash from / (used in) financing activities<br>(item 3.10 above) | 13,405                     | 14,632                                 |
| 4.5                                  | Effect of movement in exchange rates on<br>cash held                | (96)                       | (68)                                   |
| 4.6                                  | <b>Cash and cash equivalents at end of<br/>period</b>               | <b>11,479</b>              | <b>11,479</b>                          |

| 5.  | Reconciliation of cash and cash<br>equivalents<br>at the end of the quarter (as shown in the<br>consolidated statement of cash flows) to the<br>related items in the accounts | Current quarter<br>\$A'000 | Previous quarter<br>\$A'000 |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|-----------------------------|
| 5.1 | Bank balances                                                                                                                                                                 | 7,217                      | 2,462                       |
| 5.2 | Call deposits                                                                                                                                                                 | 4,262                      | 262                         |
| 5.3 | Bank overdrafts                                                                                                                                                               |                            |                             |
| 5.4 | Other (provide details)                                                                                                                                                       |                            |                             |
| 5.5 | <b>Cash and cash equivalents at end of<br/>quarter (should equal item 4.6 above)</b>                                                                                          | <b>11,479</b>              | <b>2,724</b>                |

| 6.                                                                                                                                                              | Payments to related parties of the entity and their<br>associates                          | Current quarter<br>\$A'000 |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|----------------------------|
| 6.1                                                                                                                                                             | Aggregate amount of payments to related parties and their<br>associates included in item 1 | 178                        |
| 6.2                                                                                                                                                             | Aggregate amount of payments to related parties and their<br>associates included in item 2 |                            |
| <i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i> |                                                                                            |                            |

|           |                                                                                                                                                                                                                                                                                                                                                                                            |                                                                 |                                                    |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|----------------------------------------------------|
| <b>7.</b> | <b>Financing facilities</b><br><i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i><br><i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>                                                                                                                                             | <b>Total facility<br/>amount at quarter<br/>end<br/>\$A'000</b> | <b>Amount drawn at<br/>quarter end<br/>\$A'000</b> |
| 7.1       | Loan facilities                                                                                                                                                                                                                                                                                                                                                                            | 4,540                                                           | 4,540                                              |
| 7.2       | Credit standby arrangements                                                                                                                                                                                                                                                                                                                                                                | -                                                               | -                                                  |
| 7.3       | Other (please specify)                                                                                                                                                                                                                                                                                                                                                                     | -                                                               | -                                                  |
| 7.4       | <b>Total financing facilities</b>                                                                                                                                                                                                                                                                                                                                                          | <b>4,540</b>                                                    | <b>4,540</b>                                       |
| 7.5       | <b>Unused financing facilities available at quarter end</b>                                                                                                                                                                                                                                                                                                                                |                                                                 | -                                                  |
| 7.6       | Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered or are proposed to be entered into after quarter end, include a note providing details of those facilities.                                                             |                                                                 |                                                    |
|           | A secured loan facility with Radium Capital Limited.<br>The total facility amount is \$4.54 million, of which two drawdowns (each of \$2.27 million) were advanced in December 2025 and March 2026.<br>The facility bears interest at a fixed rate of 16.5% per annum and matures on 31 December 2026. The loan is secured against the Company's expected FY2026 R&D Tax Incentive refund. |                                                                 |                                                    |

|           |                                                                                                                                                                                                                        |                |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| <b>8.</b> | <b>Estimated cash available for future operating activities</b>                                                                                                                                                        | <b>\$A'000</b> |
| 8.1       | Net cash from / (used in) operating activities (item 1.9)                                                                                                                                                              | <b>(4,456)</b> |
| 8.2       | Cash and cash equivalents at quarter end (item 4.6)                                                                                                                                                                    | <b>11,479</b>  |
| 8.3       | Unused finance facilities available at quarter end (item 7.5)                                                                                                                                                          | -              |
| 8.4       | Total available funding (item 8.2 + item 8.3)                                                                                                                                                                          | <b>11,479</b>  |
| 8.5       | <b>Estimated quarters of funding available (item 8.4 divided by item 8.1)</b>                                                                                                                                          | 2.6            |
|           | <i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>     |                |
| 8.6       | If item 8.5 is less than 2 quarters, please provide answers to the following questions:                                                                                                                                |                |
|           | 8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?                                                                      |                |
|           | Answer:                                                                                                                                                                                                                |                |
|           | 8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful? |                |
|           | Answer:                                                                                                                                                                                                                |                |

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

*Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.*

## Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 31 July 2026

Authorised by: By the Board  
(Name of body or officer authorising release – see note 4)

## Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.